Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.
White
H D
HD
D000077284:Abciximab; D000789:Angina, Unstable / Q000628:therapy*; D000800:Angioplasty, Balloon; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D004334:Drug Administration Schedule; D004347:Drug Interactions; D000077542:Eptifibatide; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D017202:Myocardial Ischemia / Q000517:prevention & control*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D015607:Stents; D015912:Thrombolytic Therapy
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D000077542:Eptifibatide; D000077284:Abciximab